Dyne Therapeutics (DYN) News Today $9.95 +0.71 (+7.68%) Closing price 07/25/2025 04:00 PM EasternExtended Trading$9.95 0.00 (0.00%) As of 07/25/2025 07:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock DYN Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 Time Period Dyne Therapeutics (NASDAQ:DYN) Trading Up 7.2% - Time to Buy?July 26 at 4:10 PM | marketbeat.comY Intercept Hong Kong Ltd Purchases 70,897 Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN)July 26 at 3:50 AM | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYNJuly 22, 2025 | prnewswire.comJPMorgan Chase & Co. Cuts Dyne Therapeutics (NASDAQ:DYN) Price Target to $9.00July 18, 2025 | americanbankingnews.comDyne Therapeutics, Inc. (NASDAQ:DYN) Receives Consensus Rating of "Buy" from BrokeragesJuly 18, 2025 | marketbeat.comDyne Therapeutics (NASDAQ:DYN) Shares Gap Up on Insider Buying ActivityJuly 18, 2025 | americanbankingnews.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYNJuly 17, 2025 | prnewswire.comSatellos Bioscience names new chief medical officerJuly 16, 2025 | msn.comDyne Therapeutics (NASDAQ:DYN) Shares Gap Up After Insider Buying ActivityJuly 16, 2025 | marketbeat.comSatellos Appoints Dr. Wildon Farwell as Chief Medical OfficerJuly 16, 2025 | businesswire.comInsider Buying: Dyne Therapeutics, Inc. (NASDAQ:DYN) CEO Acquires 100,000 Shares of StockJuly 16, 2025 | insidertrades.comDyne Therapeutics (NASDAQ:DYN) Stock Price Down 6.1% on Analyst DowngradeJuly 16, 2025 | americanbankingnews.comDyne Therapeutics, Inc. (NASDAQ:DYN) CEO John Cox Buys 100,000 SharesJuly 15, 2025 | marketbeat.comDyne Therapeutics (NASDAQ:DYN) Shares Down 6.1% on Analyst DowngradeJuly 15, 2025 | marketbeat.comJPMorgan Chase & Co. Issues Pessimistic Forecast for Dyne Therapeutics (NASDAQ:DYN) Stock PriceJuly 15, 2025 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYNJuly 14, 2025 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On ... - MorningstarJuly 13, 2025 | morningstar.comMINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYNJuly 12, 2025 | prnewswire.comDyne Therapeutics price target lowered to $41 from $46 at Evercore ISIJuly 12, 2025 | msn.comRBC Capital Maintains a Buy Rating on Dyne Therapeutics (DYN) With a $25 PTJuly 11, 2025 | finance.yahoo.comDyne Therapeutics (NASDAQ:DYN) Trading Up 6.9% - Should You Buy?July 9, 2025 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYNJuly 7, 2025 | prnewswire.comDyne Therapeutics (NASDAQ:DYN) Stock Price Down 6.2% - Time to Sell?July 7, 2025 | marketbeat.comDyne Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional SharesJuly 2, 2025 | globenewswire.comDyne Therapeutics Secures Up to $275 Million in Debt Financing from Hercules Capital - MorningstarJuly 2, 2025 | morningstar.comMDyne Therapeutics stock falls after announcing $200 million share offeringJuly 2, 2025 | investing.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYNJuly 2, 2025 | prnewswire.comDyne Therapeutics (NASDAQ:DYN) Shares Gap Down - Here's What HappenedJuly 1, 2025 | marketbeat.comDyne Therapeutics Announces Pricing of $200.0 Million Public Offering of Common StockJune 30, 2025 | globenewswire.comDyne Therapeutics Stock Down Following Secondary Offering, Debt FinancingJune 30, 2025 | marketwatch.comDyne Therapeutics, Inc. Announces $200 Million Public Offering of Common StockJune 30, 2025 | quiverquant.comQDyne Therapeutics Announces Proposed Public Offering of Common StockJune 30, 2025 | globenewswire.comDyne Therapeutics Secures Up to $275 Million in Debt Financing from Hercules CapitalJune 30, 2025 | globenewswire.comJones Trading initiates Dyne Therapeutics stock with buy ratingJune 27, 2025 | investing.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYNJune 27, 2025 | prnewswire.comDyne Therapeutics (NASDAQ:DYN) Upgraded at Jones TradingJune 27, 2025 | marketbeat.comJones Trading Initiates Coverage of Dyne Therapeutics (DYN) with Buy RecommendationJune 26, 2025 | msn.comJones Trading Begins Coverage on Dyne Therapeutics (NASDAQ:DYN)June 26, 2025 | marketbeat.comDyne Therapeutics (NASDAQ:DYN) Shares Down 5.4% - Here's WhyJune 25, 2025 | marketbeat.comDyne Therapeutics Receives FDA Breakthrough Therapy Designation for DM1 Drug DYNE-101June 24, 2025 | msn.comDyne Therapeutics (NASDAQ:DYN) Coverage Initiated by Analysts at Sanford C. BernsteinJune 24, 2025 | marketbeat.comDyne Therapeutics Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - DYNJune 24, 2025 | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Dyne Therapeutics, Inc. – DYNJune 23, 2025 | globenewswire.comDyne Therapeutics, Inc. (NASDAQ:DYN) Receives Average Recommendation of "Buy" from BrokeragesJune 23, 2025 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYNJune 22, 2025 | prnewswire.comParent Project Muscular Dystrophy Hosts 2025 Annual Conference in Las Vegas, NevadaJune 18, 2025 | finance.yahoo.comDyne at ‘attractive entry point’ following pullback, says ChardanJune 18, 2025 | finance.yahoo.comDyne Therapeutics - Emergence As A Superior DM1 / DMD Player Warrants Rating UpgradeJune 18, 2025 | seekingalpha.comDyne Therapeutics' (DYN) "Buy" Rating Reiterated at GuggenheimJune 18, 2025 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYNJune 18, 2025 | globenewswire.com Get Dyne Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for DYN and its competitors with MarketBeat's FREE daily newsletter. Email Address DYN Media Mentions By Week DYN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. DYN News Sentiment▼0.911.07▲Average Medical News Sentiment DYN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. DYN Articles This Week▼47▲DYN Articles Average Week Get Dyne Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for DYN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Avidity Biosciences News Today Akero Therapeutics News Today ADMA Biologics News Today Scholar Rock News Today Zai Lab News Today Arcellx News Today PTC Therapeutics News Today ACADIA Pharmaceuticals News Today Viking Therapeutics News Today SpringWorks Therapeutics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:DYN) was last updated on 7/26/2025 by MarketBeat.com Staff From Our PartnersWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredIt’s my duty to share the “truth” I see behind this bible verseFormer CIA advisor Jim Rickards believes President Trump has just unlocked what the Bible foretold — a $150 tr...Paradigm Press | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredI’d rather trade news like this than gamble on hypeReal traders are watching Nvidia’s next move—after U.S. approval to resume chip sales to China. This reversal ...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dyne Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Dyne Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
